Compare Brunswick Corporation (BC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Novavax Inc — how do they compare? Brunswick Corporation trades at $78.94 (market cap $5.28B), while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Brunswick Corporation is far larger — about 4× Novavax Inc's market cap, and Brunswick Corporation pays a 2.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| BC | NVAX | |
|---|---|---|
Market Cap | $5.28B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $11.19 |
52-Week Low | $58.75 | $6.22 |
Enterprise Value | $7.28B | $889.30M |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC trades at $80.43, down 1.37% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $1.56 versus $1.19 estimated, and the company maintains a dividend payout. Despite negative net income margins and ROE, revenue trends show stabilization, and cash flow from operations remains positive at $562.10M for 2025.
The outlook is cautiously optimistic, driven by earnings beats and a consensus price target of $85.33, but risks include persistent unprofitability and high debt levels. Investors may find opportunity in the bullish technical setup and institutional buying, though margin pressures and competitive challenges warrant close monitoring.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
